Cooley Helps Crescendo in $270 Million Sale to Myriad
PALO ALTO — South San Francisco's Crescendo Bioscience Inc., a maker of rheumatoid arthritis tests, and a Palo Alto team from Cooley hit a high note on the company's $270 million acquisition by Myriad Genetics Inc. Salt Lake City-based Myriad, a molecular diagnostic company that last year was at the center of a high-profile Supreme Court patent case, tapped Mintz, Levin, Cohn, Ferris, Glovsky and Popeo of Boston for legal counsel.
This article has been archived, and is no longer available on this website.
Not a LexisNexis® Subscriber?
For questions call 1-877-256-2472 or contact us at email@example.com